Plasma IL-8 and PD-L1 and overall survival in metastatic castration-resistant prostate cancer patients (mCRPC). This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does ...

Thanks to major progress in the understanding and management of rare congenital diseases and syndromes, many patients with these rare disorders are now living longer lives. With this progress it has ...